Arizona State University Institutional Animal Care and Use Committee STANDARD INSTITUTIONAL GUIDELINE

ANALGESIA

It is the policy of the IACUC that appropriate analgesic agents will be administered to animals utilized in approved research and teaching protocols. The analgesics listed in this SIG are guidelines from the DACT veterinary staff. We strongly recommend you discuss analgesic choices with the DACT veterinarians prior to submitting your protocol to determine the most effective analgesic regime for your project.

General Information

- 1. The process of pain stimulation, transmission, perception, and reaction is complex and varies greatly between species and even on an individual basis. Neuroanatomy and physiology is similar among most mammals. While the data for non-mammalian vertebrates is limited, it is best to assume that these species can also experience pain in a similar manner.
- 2. DACT veterinarians are available for consultation and training on proper analgesic usage and techniques.
- 3. According to the Animal Welfare Act (AWA), which covers mammals other than laboratory rats and mice, a painful procedure is defined as "...any procedure that would reasonably be expected to cause more than slight and momentary pain or distress in a human being to which that procedure was being applied." The Office of Laboratory Animal Welfare's (OLAW's) Public Health Service Policy on Humane Care and Use of Laboratory Animals, which can cover all vertebrates, states that "unless the contrary is established, investigators should consider that procedures that cause pain or distress in human beings may cause pain or distress in other animals." Many species of animals may not show obvious responses to painful stimuli, and the interpretation of the lack of such responses is difficult. Thus, it is best to use a generous assessment of the potential for a procedure to cause pain and to use analgesics when the presence of pain is uncertain.
- 4. Withholding the use of analgesic agents for procedures known or reasonably suspected to cause pain must be scientifically justified and approved by the IACUC. Even in cases where a scientific justification is provided and accepted by the IACUC, the experimental protocol that induces the pain and distress should be revisited on an annual basis to ascertain whether alternative approaches, drugs, or endpoints can be developed and implemented.

Choice of Analgesic Agents

1. The recommended analgesic agents, dosages, and routes of administration originate from a number of different sources including:

Carpenter, J. W. 2018. *Exotic Animal Formulary, 5th ed.*, Elsevier, St. Louis, MO. Plumb, D. C. 2018 *Veterinary Drug Handbook, 9th ed.*. Wiley-Blackwell Publishing, Ames, IA.

Hubbell, J. A. E., and Muir, W. W. 1996. Evaluation of a survey of the diplomats of the American College of Laboratory Animal Medicine on use of analgesic agents in animals used in biomedical research, *Journal of the American Veterinary Medical Association* 209: 918-921.

Fish, R. E., Brown, M. J., Danneman, P. J., and Karas, A. Z. 2008. *Anesthesia and Analgesia in Laboratory Animals, 2nd ed.*, Elsevier, St. Louis, Mo.

- 2. The tables below identify the analgesic agents (along with appropriate dosages, routes of administration, and duration of effect) recommended for the various species used in research/teaching protocols at ASU. Categories of analgesic agents include:
 - A. Narcotics (work at the level of the brain and spinal cord)
 - a. opioid agonists
 - i. provide substantial analgesia
 - ii. depress cardiovascular and respiratory activity
 - b. opioid agonist-antagonists
 - i. provide moderate to substantial analgesia
 - ii. do not depress cardiovascular and respiratory activity
 - B. Non-steroidal anti-inflammatory drugs (NSAIDs)
 - a. provide mild to moderate analgesia
 - b. may have antipyretic effects
 - c. decrease inflammation
 - C. Local analgesics (works at the site of administration)
 - a. Provides analgesia only at the site administered (unless used as a regional nerve block)

Note – because analgesics can work at different sites of the pain pathway (locally, spinal cord, brain), concurrent use of drugs acting at different sites (i.e., multi-modal analgesia) is highly recommended.

Species	Drug Type	Drug Name	Dose	Route	Frequency
	Opioid	Buprenorphine	0.05-0.1 mg/kg	IP, SC	q6-12h
	Opioid	Buprenorphine ER	0.5-1 mg/kg	SC	Lasts 72 hrs
	SpeciesDrug TypeDrug NameDoseOpioidBuprenorphine0.05-0.1 mg/kgOpioidBuprenorphine ER (Ethiqa XR)0.5-1 mg/kgOpioidBuprenorphine ER (Ethiqa XR)3.25 mg/kgNSAIDMeloxicam1-5 mg/kgNSAIDCarprofen2-5 mg/kgNSAIDMediGel CPF 	SC	Lasts 72 hrs		
	NSAID	Meloxicam	1-5 mg/kg	SC, PO	q24h
	NSAID	Carprofen	2-5 mg/kg	SC, PO	q24h
Mouse	Mouse NSAID MediGel CPF (carprofen) 5 mg/kg/day oral Local Bupivacaine max of 2.5 mg/kg topical, infiltrate	oral	ad lib		
	Local	Bupivacaine (Marcaine®) 0.25%	For fen)5 mg/kg/dayoralaine (2) 0.25%max of 2.5 mg/kgtopical, infiltrationmax of 2 mg/kgtopical infiltration	topical, infiltrate	Onset 20-30 mins, lasts 3- 5 hours
	Local	Lidocaine 2%	max of 2 mg/kg	topical, infiltrate	Onset 1-2 mins, lasts 1- 2 hours
	Opioid	Buprenorphine	0.02-0.1 mg/kg	IP, SC	q6-12h
	DeciesDrug TypeDrug NameDoseOpioidBuprenorphine0.05-0.1 mg/kgOpioidBuprenorphine ER (Ethiqa XR)0.5-1 mg/kgOpioidBuprenorphine ER (Ethiqa XR)3.25 mg/kgNSAIDMeloxicam1-5 mg/kgNSAIDCarprofen2-5 mg/kgNSAIDMediGel CPF (carprofen)5 mg/kg/dayLocalBupivacaine (Marcaine®) 0.25%max of 2.5 mg/kgLocalLidocaine 2%max of 2 mg/kgOpioidBuprenorphine ER (Ethiqa XR)1-1.2 mg/kgOpioidBuprenorphine ER (Ethiqa XR)0.65 mg/kgNAIDMeloxicam1-2 mg/kgNAIDMeloxicam1-2 mg/kgNAIDMeloxicam1-2 mg/kgNAIDMeloxicam1-2 mg/kgNAIDMeloxicam1-2 mg/kg	SC	Lasts 72 hrs		
Rat	Opioid	Buprenorphine ER (Ethiqa XR)	0.65 mg/kg	SC	Lasts 72 hrs
	NSAID	Bupivacaine (Marcaine®) 0.25%max of 2.5 mg/kgtopicLidocaine 2%max of 2 mg/kgtopicBuprenorphine0.02-0.1 mg/kgBuprenorphine ER (Ethiqa XR)1-1.2 mg/kgMeloxicam1-2 mg/kgCarprofen MediGel CPF5 mg/kg/day	SC, PO	q24h	
	NSAID	Carprofen	2-5 mg/kg	SC, PO	q24h
	NSAID	MediGel CPF	5 mg/kg/day	oral	ad lib

		(carprofen)			
	Local	Bupivacaine (Marcaine [®]) 0.25%	max of 2.5 mg/kg	topical, infiltrate	Onset 20-30 mins, lasts 3- 5 hours
	Local	Lidocaine 2%	max 2 mg/kg	topical, infiltrate	Onset 1-2 mins, lasts 1- 2 hours
	Opioid	Buprenorphine	0.01-0.03 mg/kg	SC, IM	q6-12h
	Opioid	Buprenorphine ER	0.2 mg/kg	SC	Lasts 72 hrs
	Local Bupivacaine (Marcaine®) 0.25% max of 2.5 mg/kg topical, infilt Local Lidocaine 2% max 2 mg/kg topical, infilt Opioid Buprenorphine 0.01-0.03 mg/kg SC, IM Opioid Buprenorphine ER 0.2 mg/kg SC Opioid Buprenorphine ER 0.2 mg/kg SC Opioid Buprenorphine ER 0.2 mg/kg SC Opioid Oyioid- (Ethiqa XR) 0.2 mg/kg SC, IM, IN Opioid Oyioid- Iike Tramadol 2 mg/kg PO NSAID Meloxicam 0.2 mg/kg once, then 0.1 mg/kg SC, PO NSAID Meloxicam 1 mg/kg (max of 2.5 mg/kg) topical, infilt opioid Bupivacaine (Marcaine®) 0.25% 1 mg/kg (max of 2.5 mg/kg) topical, infilt set Opioid Buprenorphine 0.01-0.05 mg/kg SC, IM, IP, Opioid Buprenorphine 0.10-0.5 mg/kg SC, IM, IP, Opioid Buprenorphine 0.15 mg/kg SC, IM, IP, Opioid Buprenorphine ER 0.15 mg/kg	SC	Lasts 72 hrs		
	Opioid	Oxymorphone	0.15 mg/kg	SC, IM, IV	q4-6h
	Opioid	Hydromorphone	0.05-0.2 mg/kg	SC, IM, IV	q4-6h
Macaque	Opioid- like	Tramadol	2 mg/kg	РО	q12h
	NSAID	Meloxicam	0.2 mg/kg once, then 0.1 mg/kg	SC, PO	q24h
	NSAID	Meloxicam ER	0.6 mg/kg	SC	Lasts 72 hrs
	Local	Bupivicaine (Marcaine®) 0.25%	1 mg/kg (max of 2.5 mg/kg)	topical, infiltrate	N/A
	Opioid	Buprenorphine	0.005-0.02 mg/kg	SC, IM	q6-12h
Marmoset	NSAID	Meloxicam	0.2 mg/kg once, then 0.1 mg/kg	SC, PO	q24h
	Local	Bupivacaine (Marcaine [®]) 0.25%	1 mg/kg (max of 2.5 mg/kg)	topical, infiltrate	N/A
	Opioid	Buprenorphine	0.01-0.05 mg/kg	SC, IM, IP, IV	q6-12h
	Opioid	Buprenorphine ER (Ethiqa XR)	0.15 mg/kg	SC	Lasts 72 hrs
Rabbit	Opioid	Butorphanol	0.1-0.5 mg/kg	'kg SC, IM e, SC, PO of topical, infiltrate kg SC, IM, IP, IV SC SC g SC, IM, IV g SC, PO 2.5 topical, infiltrate	q4-6h
	NSAID	Opioid Buprenorphine 0.01-0.05 mg/kg SC, IM, IP, IV Opioid Buprenorphine ER (Ethiqa XR) 0.15 mg/kg SC Opioid Butorphanol 0.1-0.5 mg/kg SC, IM, IV NSAID Meloxicam 0.2-0.3 mg/kg SC, PO	q24h		
	Local	Bupivacaine (Marcaine®) 0.25%	1 mg/kg (max 2.5 mg/kg)	topical, infiltrate	N/A
	Opioid	Buprenorphine	0.05-0.1 mg/kg	SC	q6-12h
Guinea	Opioid	Buprenorphine ER (Ethiqa XR)	0.48 mg/kg	SC	Lasts 72 hrs
Pig/Chinchilla	NSAID	Meloxicam	0.5 mg/kg	SC, PO	q24h
	Local	Bupivacaine (Marcaine®) 0.25%	max of 2.5 mg/kg	topical, infiltrate	N/A
	Opioid	Buprenorphine	0.01-0.03 mg/kg	IM	q6-8h
Cat	Opioid	Buprenorphine ER	0.12 mg/kg	SC	Lasts 72 hrs
Cat	Opioid	Hydromorphone	0.05-0.1 mg/kg	SC, IM, IV	q4-6h
	NSAID	Meloxicam	0.3 mg/kg	SC	Once

	Opioid	Butorphanol	0.5-4 mg/kg	IM	q1-4h
*Bird	NSAID	Meloxicam	0.1-0.2 mg/kg	IM, PO	q24h
	Local	Lidocaine gel	2%	topical	N/A
**Amphibians	Opioid	Butorphanol	0.2-0.4 mg/kg	IM	q4-6h; efficacy uncertain
	Local	Lidocaine gel	2%	topical	N/A
**Reptiles	Local	Bupivacaine (Marcaine [®]) 0.25%	1-2 mg/kg (max of 4 mg/kg)	topical, infiltrate	N/A

* There is wide variation in drug dosages depending on different bird species. Consult with the DACT veterinarians for dosages specific to your project.

**The effectiveness of analgesics in amphibians and reptiles is poorly known, and many doses in the literature have limited, if any, evidence to support them as being safe and effective. Consult with the DACT veterinarians for the appropriateness of analgesics for your specific project.

Drug Enforcement Agency (DEA) schedule for controlled substances listed in the table:

Buprenorphine	schedule 3
Buprenorphine ER	schedule 3
Butorphanol	schedule 4N
Hydromorphone	schedule 2
Oxymorphone	schedule 2
Tramadol	schedule 4
Other drugs listed in	the table are not DEA-controlled substances.

Grimace Scale for Mice, Rats, Rabbits

1. Changes in facial expression is a reliable way to assess pain in various species. Researchers have demonstrated specific changes that occur in mice, rats, and rabbits to develop grimace scales for each species. More information can be found at https://www.nc3rs.org.uk/3rs-resources/grimace-scales.

NC National Centre for the Replacement Refinement & Reduction of Animals in Research 3R^s

The Mouse Grimace Scale

The specific facial action units shown below have been used to generate the Mouse Grimace Scale. These action units increase in intensity in response to post-procedural pain and can be used as part of a clinical assessment. The action units should only be used in awake animals. Each animal should be observed for a short period of time to avoid scoring brief changes in facial expression that are unrelated to the animal's welfare.

	Not present "0"	Moderately present "I"	Obviously present "2"
 Orbital tightening Closing of the eyelid (narrowing of orbital area) A wrinkle may be visible around the eye 			
Nose bulge ■ Bulging on the bridge of the nose ■ Vertical wrinkles on the side of the nose			
Cheek bulge ■ Bulging of the cheeks			
 Ear position Ears rotate outwards and/or backwards, away from the face Ears may fold to form a 'pointed' shape Space between the ears increases 			
 Whisker change Whiskers are either pulled back against the cheek, or pulled forward to 'stand on end' Whiskers may clump together Whiskers lose their natural 'downward' curve 			

Read the original paper: Langford DJ, Bailey AL, Chanda ML, Clarke SE, Drummond TE, Echols S, Glick S, Ingrao J, Klassen-Ross T, LaCroix-Fralish ML, Matsumiya L, Sorge RE, Sotocinal SG, Tabaka JM, Wong D, van den Maagdenberg AMJM, Ferrari MD, Craig KD, Mogil JS. 2010. Coding of facial expressions of pain in the laboratory mouse. Nature Methods 7(6): 447-449. doi:10.1038/nmeth.1455

For guidance on using the Mouse Grimace Scale, research papers that underpin this technique, and for grimace scales in other species, visit: www.nc3rs.org.uk/grimacescal To request copies of this poster, please email: enquiries@nc3rs.org.uk The NC3Rs provides a range of 3Rs resources at: www.nc3rs.org.uk/resources

Revised 1/23/2025 Revised 12/14/2023 Revised 11/17/2022

. S



National Centre for the Replacement Refinement & Reduction of Animals in Research

The Rat Grimace Scale

Research has demonstrated that changes in facial expression provide a means of assessing pain in rats.

Rat Grimace Scale. These action units increase in intensity in response to post-procedural pain and can be used as part of a clinical assessment.

The specific facial action units shown below have been used to generate the 💿 The action units should only be used in awake animals. Each animal should be observed for a short period of time to avoid scoring brief changes in facial expression that are unrelated to the animal's welfare.



Read the original paper: Sotocinal SG, Sorge RE, Zaloum A, Tuttle AH, Martin LJ, Wieskopf JS, Mapplebeck JCS, Wei P, Zhan S, Zhang S, McDougall JJ, King OD, Mogil JS. 2011. The Rat Grimace Scale: a partially automated method for quantifying pain in the laboratory rat via facial expressions. Molecular Pain 7: 55. doi:10.1186/1744-8069-7-55

For guidance on using the Rat Grimace Scale, research papers that underpin this technique, and for grimace scales in other species, visit: www.nc3rs.org.uk/grimacescales To request copies of this poster, please email: enquiries@nc3rs.org.uk/resources The NC3Rs provides a range of 3Rs resources at: www.nc3rs.org.uk/resources Images kindly provided by Dr Jeffrey Mogil, McGill University



National Centre for the Replacement Refinement & Reduction of Animals in Research



The Rabbit Grimace Scale

Research has demonstrated that changes in facial expression provide a means of assessing pain in rabbits.

The specific facial action units shown below comprise the Rabbit Grimace Scale. These action units increase in intensity in response to post-procedural pain and can form part of a clinical assessment alongside other validated indices of pain.

The action units should only be used in awake animals. Each animal should be observed for a short period of time to avoid scoring brief changes in facial expression that are unrelated to the animal's welfare.

	Action units			
	Not present "0"	Moderately present "I"	Obviously present "2"	
Orbital tightening Closing of the eyelid (narrowing of orbital area) A wrinkle may be visible around the eye				
 Cheek flattening Flattening of the cheeks. When 'obviously present', cheeks have a sunken look. The face becomes more angular and less rounded 				
Nostril shape • Nostrils (nares) are drawn vertically forming a 'V' rather than 'U' shape • Nose tip is moved down towards the chin				
Whisker shape and position • Whiskers are pushed away from the face to 'stand on end' • Whiskers stiffen and lose their natural, downward curve • Whiskers increasingly point in the same direction. When 'obviously present', whiskers move downwards Ear shape and position				
 Ears become more tightly folded / curled (more cylindrical) in shape Ears rotate from facing towards the source of sound to facing towards the hindquarters Ears may be held closer to the back or sides of the body 				

Read the original paper. Keating SCJ, Thomas AA, Flecknell PA, Leach MC (2012) Evaluation of EMU2 cream for preventing pain during tattooing of rabbits: Changes in physiological, behavioural and facial expression responses. PLOS ONE 7(9): e44437. doi:10.1371/journal.pone. 0044437 For guidance on using the Rabbit Grimace Scale, additional images of each action unit, research papers that underpin this technique, and for grimace scales in other species, visit: www.nc3rs.org.uk/grimacescales To request copies of this poster, please email: enquiries@nc3rs.org.uk The NC3Rs provides a range of 3Rs resources at www.nc3rs.org.uk/resources Images kindly provided by Dr Matthew Leach, Newcastle University The Rabbit Grimace Scale would not have been developed without the continuing work of the Pain and Animal Welfare Sciences Group (PAWS) at Newcastle University

17:37